Clinical trials / Georgia
Psychedelic and ketamine trials recruiting in Georgia
8 trials registered on ClinicalTrials.gov were recruiting at one or more sites in Georgia on 26 Oct 2026. By substance: Ketamine / esketamine 5, Psilocybin 2, MDMA 1. By condition: depression 5, ptsd 2.
From the ClinicalTrials.gov registry (US National Library of Medicine), read through its public API on 26 Oct 2026: studies marked as recruiting whose interventions name the substance. Titles, sponsors, phases, conditions and sites are the registry's own entries, written by the sponsors. We have not vetted any trial, and recruiting status changes; the registry record and the study team have the current eligibility rules.
Phase 3Ketamine / esketamineNCT07227454
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder (AVENUE)
- Conditions:
- Depressive Disorder, Major
- Sponsor:
- Janssen Research & Development, LLC
- Who:
- ages 12 Years to 17 Years, 258 participants planned
- Also in:
- Brazil, Hungary, Italy, Romania, Spain, Taiwan
- Peachford Hospital-Atlanta Behavioral Research, Atlanta, Georgia
Phase 3Ketamine / esketamineNCT07716098
A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression
- Conditions:
- Depressive Disorder, Treatment-Resistant
- Sponsor:
- Janssen Research & Development, LLC
- Who:
- ages 18 Years and over, 348 participants planned
- Also in:
- Japan, Taiwan
- Psych Atlanta, P.C., Marietta, Georgia
Phase 3Ketamine / esketamineNCT06713616
PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study
- Conditions:
- Depression
- Sponsor:
- Yale University
- Who:
- ages 18 Years and over, 400 participants planned
- Emory University, Atlanta, Georgia
ObservationalKetamine / esketamineNCT06725277
The OBSERVE Protocol
- Conditions:
- Major Depression Disorder
- Sponsor:
- Yale University
- Who:
- 450 participants planned
- Emory University, Atlanta, Georgia
Phase 1PsilocybinNCT07516405
Safety and Tolerability Trial of Psilocybin in Healthy Older Adults (Psil-Pk)
- Conditions:
- Healthy Volunteer; Older Adults (65-85 Years)
- Sponsor:
- University of Colorado, Denver
- Who:
- ages 65 Years to 85 Years, 40 participants planned, accepts healthy volunteers
- Emory University Brain Health Center, Atlanta, Georgia
Early phase 1Ketamine / esketamineNCT05327699
Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine
- Conditions:
- Major Depressive Disorder
- Sponsor:
- Emory University
- Who:
- ages 18 Years to 65 Years, 140 participants planned, accepts healthy volunteers
- Emory University, Atlanta, Georgia
Phase 2MDMANCT07288151
MDMA-Assisted Massed Exposure Therapy for PTSD
- Conditions:
- Post Traumatic Stress Disorder
- Sponsor:
- Emory University
- Who:
- ages 21 Years to 70 Years, 200 participants planned
- Emory Brain Health Center, Atlanta, Georgia
Phase 2PsilocybinNCT07332143
Psilocybin-Assisted Therapy
- Conditions:
- PTSD
- Sponsor:
- Emory University
- Who:
- ages 18 Years and over, 150 participants planned
- Emory University Hospital, Atlanta, Georgia